Compassionate Capitalism

In the final feature of Big4Bio’s Company to Watch program, we spoke with Venatorx Pharmaceuticals’ board member, Vincent Milano, about why he thinks the company is worth watching. Milano has more than 25 years of experience in biotechnology, first at ViroPharma, which was acquired by Shire, and currently as CEO of Idera Pharmaceuticals. Company to […]

Read More

A Discovery Engine That Keeps on Cranking

Company to Watch – Venatorx Pharmaceuticals As May’s Company to Watch program concludes, Big4Bio shares thoughts from Venatorx’s Founder and Senior Vice President, Biology and Grants Development, Daniel Pevear, Ph.D., about why Venatorx is a company worth watching. by Marie Daghlian When Chris Burns, Luigi Xerri, and Dan Pevear left Novartis after it cut loose […]

Read More

Podcast: An Innovative Approach to Treating Multi-Drug Resistant Bacterial Infections

Company to Watch – Venatorx Pharmaceuticals   As part of May’s Company to Watch program, we spoke to Christopher Burns, founder, president, and CEO of Venatorx, about the need for new means of combating multi-drug resistant microbes, the company’s combination therapies in development, and its success at advancing its pipeline with non-dilutive funding.   NEXT: […]

Read More

Targeting Antivirals With Program for Hepatitis B

Company to Watch – Venatorx Pharmaceuticals For more than ten years, Venatorx Pharmaceuticals has used its medicinal chemistry chops to develop a robust pipeline of novel anti-infectives that address multi-drug resistant bacterial infections — superbugs that could become the next pandemic — and hard-to-treat viral infections. On day three of this series, we focus on […]

Read More

A Novel Inhibitor Platform Impervious to Beta-Lactamases

Company to Watch – Venatorx Pharmaceuticals For more than ten years, Venatorx Pharmaceuticals has used its medicinal chemistry chops to develop a robust pipeline of novel anti-infectives that address multi-drug resistant bacterial infections — superbugs that could become the next pandemic — and hard-to-treat viral infections. We continue to explore the company’s pipeline in this […]

Read More

Venatorx Pharmaceuticals’ Novel Antibiotic Pipeline Addresses the Next Pandemic: Superbugs

Company to Watch – Venatorx Pharmaceuticals For more than ten years, Venatorx Pharmaceuticals has used its medicinal chemistry chops to develop a robust pipeline of novel anti-infectives that address multi-drug resistant bacterial infections — superbugs that could become the next pandemic — and hard-to-treat viral infections. We will explore the company’s pipeline over the next […]

Read More

Venatorx Pharmaceuticals – The Drug Hunter Flying Under the Radar

Company to Watch – Venatorx Pharmaceuticals by Marie Daghlian In 2010, Drs. Christopher Burns, Daniel Pevear, and Luigi Xerri set out to build a new company focused on anti-infectives, and named it Venatorx, which loosely translated means “Drug Hunter.” Their ambition was to invent novel classes of antibiotics with novel mechanisms of action. And this […]

Read More

The Big4Bio Company to Watch Program
September 2021: Molecular Assemblies

THE COMPANY/THE MISSION Changing the Paradigm for Writing DNA Molecular Assemblies’ leaders detail how the company got started, the company’s technology for synthesizing DNA, and why that technology is better than current methods.     THE TECHNOLOGY, PART 1 Moving Synthetic Biology into the 21st Century A deeper look at the company’s enzymatic DNA synthesis […]

Read More

The Big4Bio Company to Watch Program
May 2021: Venatorx Pharmaceuticals

THE COMPANY/THE MISSION The Drug Hunter Flying Under the Radar In 2010, Drs. Christopher Burns, Daniel Pevear, and Luigi Xerri set out to build a company focused on anti-infectives; they named it Venatorx, which loosely translated means “Drug Hunter.”   THE PIPELINE Addressing the Next Pandemic: Superbugs Venatorx’s lead clinical-stage antibiotics address the growing problem […]

Read More